Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

Alkermes plc's (NASDAQ:ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan) met its prespecified primary endpoint on body weight in young schizophrenia adult patients in the early stage of the disease. 

  • Patients treated with Lybalvi experienced statistically significantly less weight gain than patients treated with olanzapine at Week 12 (6.77% for olanzapine vs. 4.91% for Lybalvi). 
  • Lybalvi is approved for schizophrenia and for treating adults with bipolar I disorder as a maintenance monotherapy or acute manic or mixed episodes as monotherapy or an adjunct to lithium or valproate.
  • Also See: Janssen Partially Terminates Nanoparticle License Agreement With Alkermes.
  • The study employed a hierarchical testing methodology for four prespecified secondary endpoints. 
  • The first secondary endpoint did not achieve the prespecified significance level. A numerical difference was observed between treatment arms across all secondary endpoints in favor of Lybalvi. 
  • At three months, the proportion of patients who gained 10% or more of their baseline body weight was 30.4% for olanzapine vs. 21.9% for Lybalvi.
  • The mean change from baseline in waist circumference at three months was 3.90 cm for patients treated with olanzapine vs. 2.99 cm for patients treated with Lybalvi.
  • Price Action: ALKS shares are down 2.00% at $23.08 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.